← Browse by Condition
Medical Condition

amyloidosis

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for amyloidosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — amyloidosis Clinical Trials

How many clinical trials are currently recruiting for amyloidosis?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for amyloidosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for amyloidosis?
amyloidosis research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a amyloidosis clinical trial?
Eligibility criteria for amyloidosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
University Hospital Heidelberg 1 trial
Barbara Ann Karmanos Cancer Institute 1 trial
University of Alabama at Birmingham 1 trial
University Hospital, Toulouse 1 trial
Sinocelltech Ltd. 1 trial

Recruiting Clinical Trials

NCT04265040
Recruiting
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
Enrollment
2,040 pts
Location
Germany
Sponsor
University Hospital Heidelberg
View Trial →
NCT05738005
Recruiting
Dietary Reporting In The Amyloidoses
Enrollment
40 pts
Location
United States
Sponsor
Barbara Ann Karmanos Cancer In...
View Trial →
NCT04991103 Phase 2
Recruiting
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Enrollment
40 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT04636684
Recruiting
Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis
Enrollment
100 pts
Location
France
Sponsor
University Hospital, Toulouse
View Trial →
NCT07388602 Phase 3
Recruiting
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
Enrollment
90 pts
Location
China
Sponsor
Sinocelltech Ltd.
View Trial →
NCT06539169
Recruiting
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Enrollment
1,000 pts
Location
United States
Sponsor
xCures
View Trial →
NCT06527521
Recruiting
Prevalence of Amyloidosis in Trauma Patients
Enrollment
246 pts
Location
Spain
Sponsor
Consorci Sanitari de l'Alt Pen...
View Trial →

Related Conditions

non ischemic cardiomyopathy (1) dcm dilated cardiomyopathy (1) hcm hypertrophic cardiomyopathy (1) hocm hypertrophic obstructive cardiomyopathy (1) arrhythmogenic right ventricular cardiomyopathy (1) left ventricular noncompaction cardiomyopathy (1) inflammatory cardiomyopathy (1) multiple myeloma (1) alpha thalassemia (1) beta thalassemia (1) amyotrophic lateral sclerosis (1) creutzfeld jakob disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology